Roche Pakistan products and prices in Pakistan
Importer / marketer Its products are registered under a DRAP Drug Sale Licence (DSL), typically imported finished products. Source: DRAP.
Follow price changes 🔒 Company report (Pharma Pro)Public unlisted pharmaceutical and diagnostics company - Roche group · Karachi · Pakistan
Pakistan affiliate of the Roche Group, active in innovative medicines, diagnostics and patient-support initiatives.
Roche Pakistan products in Pakistan
Roche Pakistan Ltd has 16 medicine presentations registered in Pakistan under 10 brands, covering 7 generic medicines. Most of its products are in Oncology & immunology, Gastrointestinal & hepatology and Hematology & thrombosis. Its brands with the most registered strengths and packs are Avastin (Bevacizumab), Mabthera (Rituximab), Mircera (Methoxy polyethylene glycol-epoetin beta) and Recormon PFS (Epoetin beta). 16 products have an official DRAP price on MedInfoBase. See all 10 brands A to Z
What is sourced, and how recent is it?
Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.
Company profile
- Legal / official name
- Roche Pakistan Limited
- Company type
- Public unlisted pharmaceutical and diagnostics company - Roche group
- Address
- 11th Floor, Al-Tijarah Centre, Plot 32-1-A, Block 6, P.E.C.H.S., Karachi 75400, Pakistan · 75400
- Website
- roche.com.pk ↗
- Phone
- +92 21 34538890-1
- Official contact
- Contact page ↗
- Corporate source details checked
- 16 Aug 2026
- Corporate profile completeness
- 88%
Company location
A sourced company location is recorded. Use the map link below for directions.
Portfolio at a glance
RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.
PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.
IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.
Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.
Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.
Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.
How complete is this profile?
Downloadable company intelligence charts
Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.
Therapeutic Portfolio Mix
Shows where the company portfolio is concentrated across broad therapeutic areas.
Portfolio distribution, not sales or market-share data.
Dosage Form Portfolio
Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.
Counts are product presentations, not production or sales volumes.
Equivalent Price Position
Shows whether safely comparable products are below, near or above the peer median unit price.
This is price-position intelligence, not sales, demand or market-share data.
Closest Portfolio Competitors
Highlights other manufacturers with the greatest generic overlap with this company portfolio.
Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.
Therapeutic areas
High-level clinical areas represented by this company’s current MedInfoBase portfolio.
Drug classes
More specific classes derived from the canonical generic and preserved curated classifications.
Dosage forms
How MedInfoBase classifies the portfolio
MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.
Deepest brand families
Unit-price positioning vs equivalent products
See where Roche Pakistan Ltd is priced against the market
7 of its products have like-for-like competitors. Pharma Pro shows how many are priced below, near or above the market median, the company's overall price position, and product-by-product examples.
How MedInfoBase calculates price position
Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.
Portfolio overlap
Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.
🔒 3 more overlapping companies, with shared-generic detail, in Pharma Pro. Unlock
Observed database signals
These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.
Medicine portfolio
This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.
| Brand | Generic | Strength | Form | Pack | Registration | Source-listed price | Unit price | Price position |
|---|---|---|---|---|---|---|---|---|
| Avastin | Bevacizumab | 100 mg/4 mL | Injection | 1's | 043004 | PKR 59,483.08 | PKR 59,483.08/vial/unit | 🔒 Pharma Pro |
| Avastin | Bevacizumab | 400 mg/16 mL | Concentrate for solution for infusion | 1's | 043005 | PKR 236,486.52 | PKR 236,486.52/vial/unit | 🔒 Pharma Pro |
| Eaxiron Injection 0.5gmRegistry verified | Each vial contains:- Cefotaxime (Na) ..... 500mg | — | Injection | — | 032131Official source ↗ | No indexed price | — | — |
| Herceptin | Trastuzumab | 440 mg | Powder for concentrate for infusion | 1's | 032130 | PKR 263,708.44 | PKR 263,708.44/vial/unit | No comparator |
| Herceptin SC | Trastuzumab | 600 mg/5 mL (120 mg/mL) | Subcutaneous injection | 1's | 088527 | PKR 252,394.98 | PKR 252,394.98/vial/unit | No comparator |
| Mabthera | Rituximab | 1400 mg/11.7 mL (120 mg/mL) | Solution for subcutaneous injection | 1's | 094764 | PKR 185,708.68 | PKR 185,708.68/vial/unit | No comparator |
| Mabthera | Rituximab | 1600 mg/13.4 mL (120 mg/mL) | Solution for subcutaneous injection | 1's | 094765 | PKR 211,032.59 | PKR 211,032.59/vial/unit | No comparator |
| Mircera | Methoxy polyethylene glycol-epoetin beta | 75 mcg/0.3 mL | Prefilled syringe injection | 1's | 059051 | PKR 23,816.36 | PKR 23,816.36/syringe | No comparator |
| Mircera | Methoxy polyethylene glycol-epoetin beta | 50 mcg | Prefilled syringe injection | 1's | 059052 | PKR 15,862.15 | PKR 15,862.15/syringe | No comparator |
| Mircera PFS | Methoxy polyethylene glycol-epoetin beta | 100 mcg/0.3 mL | Prefilled syringe injection | 1's | 059050 | PKR 26,436.92 | PKR 26,436.92/syringe | No comparator |
| Recormon PFS | Epoetin beta | 5000 IU | Prefilled syringe injection | 6's | 019577 | PKR 27,587.73 | PKR 4,597.96/syringe | No comparator |
| Recormon PFS | Epoetin beta | 10000 IU | Prefilled syringe injection | 6's | 019578 | PKR 46,596.00 | PKR 7,766.00/syringe | No comparator |
| Ristova | Rituximab | 100 mg/10 mL | Injection | 2's | 031394 | PKR 71,255.76 | PKR 35,627.88/vial/unit | 🔒 Pharma Pro |
| Ristova | Rituximab | 500 mg/50 mL | Injection | 1's | 031395 | PKR 176,590.37 | PKR 176,590.37/vial/unit | 🔒 Pharma Pro |
| Tamiflu , containing | Oseltamivir | 75 mg | Capsule | 10's | 039619 | PKR 2,650.16 | PKR 265.02/capsule | 🔒 Pharma Pro |
| Tarceva | Erlotinib | 100 mg | Tablet | 30's | 043002 | PKR 216,796.09 | PKR 7,226.54/tablet | 🔒 Pharma Pro |
| Tarceva | Erlotinib | 150 mg | Tablet | 30's | 043003 | PKR 270,127.02 | PKR 9,004.23/tablet | 🔒 Pharma Pro |
All 10 Roche Pakistan brands in Pakistan
- Avastin Bevacizumab · 100 mg/4 mL injection, 400 mg/16 mL infusion
- Herceptin Trastuzumab · 440 mg infusion
- Herceptin SC Trastuzumab · 600 mg/5 mL (120 mg/mL) injection
- Mabthera Rituximab · 1400 mg/11.7 mL (120 mg/mL) injection, 1600 mg/13.4 mL (120 mg/mL) injection
- Mircera Methoxy polyethylene glycol-epoetin beta · 50 mcg injection, 75 mcg/0.3 mL injection
- Mircera PFS Methoxy polyethylene glycol-epoetin beta · 100 mcg/0.3 mL injection
- Recormon PFS Epoetin beta · 10000 IU injection, 5000 IU injection
- Ristova Rituximab · 100 mg/10 mL injection, 500 mg/50 mL injection
- Tamiflu , containing Oseltamivir · 75 mg capsule
- Tarceva Erlotinib · 100 mg tablet, 150 mg tablet
Roche Pakistan: common questions
How many products does Roche Pakistan have in Pakistan?
Roche Pakistan Ltd has 16 registered medicine presentations in Pakistan, sold under 10 brands and covering 7 generic medicines.
What are the main brands of Roche Pakistan?
By number of registered strengths and packs, its largest brands are Avastin (Bevacizumab), Mabthera (Rituximab), Mircera (Methoxy polyethylene glycol-epoetin beta), Recormon PFS (Epoetin beta) and Ristova (Rituximab). This is not a sales ranking.
Which therapy areas does Roche Pakistan cover?
The most products are in Oncology & immunology (10), Gastrointestinal & hepatology (3), Hematology & thrombosis (2) and Anti-infectives (1).
Where can I see Roche Pakistan medicine prices?
Open any brand in the list above for its official DRAP price, pack sizes, price history and other brands of the same medicine.
MedInfoBase company-intelligence methodology
This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.
Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.
Cite this record
Manufacturer recordRecords change over time. Please cite the access date so readers can locate the version you used.